AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer

Early‐stage estrogen receptor positive and human epidermal growth factor receptor negative (ER+/HER2−) luminal breast cancer (BC) is quite heterogeneous and accounts for about 70% of all BCs. Ki67 is a proliferation marker that has a significant prognostic value in luminal BC despite the challenges...

Full description

Saved in:
Bibliographic Details
Published in:The journal of pathology. Clinical research 2024-01, Vol.10 (1), p.e346-n/a
Main Authors: Lu, Wenqi, Lashen, Ayat G, Wahab, Noorul, Miligy, Islam M, Jahanifar, Mostafa, Toss, Michael, Graham, Simon, Bilal, Mohsin, Bhalerao, Abhir, Atallah, Nehal M, Makhlouf, Shorouk, Ibrahim, Asmaa Y, Snead, David, Minhas, Fayyaz, Raza, Shan E Ahmed, Rakha, Emad, Rajpoot, Nasir
Format: Article
Language:English
Subjects:
AI based prognostic biomarkers
Annotations
Artificial Intelligence
Automation
Biomarkers
Breast cancer
Breast Neoplasms - pathology
Cancer therapies
Cells
Chemotherapy
Classification
computational pathology
Datasets
Endocrine therapy
ErbB-2 protein
Estrogen receptors
Female
Gene expression
Humans
Ki-67 Antigen
Ki67 expression
luminal breast cancer
Medical prognosis
Metastases
Metastasis
Original
Patients
Prognosis
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - metabolism
Reproducibility
Scanners
Spatial distribution
Spatial heterogeneity
Survival analysis
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Early‐stage estrogen receptor positive and human epidermal growth factor receptor negative (ER+/HER2−) luminal breast cancer (BC) is quite heterogeneous and accounts for about 70% of all BCs. Ki67 is a proliferation marker that has a significant prognostic value in luminal BC despite the challenges in its assessment. There is increasing evidence that spatial colocalization, which measures the evenness of different types of cells, is clinically important in several types of cancer. However, reproducible quantification of intra‐tumor spatial heterogeneity remains largely unexplored. We propose an automated pipeline for prognostication of luminal BC based on the analysis of spatial distribution of Ki67 expression in tumor cells using a large well‐characterized cohort (n = 2,081). The proposed Ki67 colocalization (Ki67CL) score can stratify ER+/HER2− BC patients with high significance in terms of BC‐specific survival (p 
ISSN:2056-4538
2056-4538
DOI:10.1002/cjp2.346